CLINUVEL Newsletter – November 2018

05 November 2018

The most recent quarterly financial results (1 July-30 September 2018) confirm the steady growth in clinical demand for SCENESSE® (afamelanotide 16mg) in erythropoietic protoporphyria (EPP), a rare genetic metabolic disorder.1 EPP is classified as a condition of high unmet medical need, and for it not to have found any alternative therapy makes the treatment with our hormonal product SCENESSE® worthwhile for patients.

Download PDF to read more

We use cookies to give you the best experience.